Martje Van Neste

Dr. Martje Van Neste

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 May 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Nina NauwelaertsNina Nauwelaerts
Nina Nauwelaerts
JMJulia Macente
Julia Macente
NDNeel Deferm
Neel Deferm
Rodolfo Hernandes BonanRodolfo Hernandes Bonan
Rodolfo Hernandes Bonan
MHMiao-Chan Huang
Miao-Chan Huang
PAPieter Annaert
Pieter Annaert
Women commonly take medication during lactation. Currently, there is little information about the exposure-related safety of maternal medicines for breastfed infants. The aim was to explore the performance of a generic physiologically-based pharmacokinetic (PBPK) model to predict concentrations in human milk for ten physiochemically diverse medicines. First, PBPK models were developed for “non-lactating” adult individuals in PK-Sim/MoBi v9.1 (Open Systems Pharmacology). The PBPK models predicted the area-under-the-curve (AUC) and maximum concentrations (Cmax) in plasma within a two-fold error. Next, the PBPK models were extended to include lactation physiology. Plasma and human milk concentrations were simulated for a three-months postpartum population, and the corresponding AUC-based milk-to-plasma (M/P) ratios and relative infant doses were calculated. The lactation PBPK models resulted in reasonable predictions for eight medicines, while an overprediction of human milk concentrations and M/P ratios (>2-fold) was observed for two medicines. From a safety perspective, none of the models resulted in underpredictions of observed human milk concentrations. The present effort resulted in a generic workflow to predict medicine concentrations in human milk. This generic PBPK model represents an important step towards an evidence-based safety assessment of maternal medication during lactation, applicable in an early drug development stage.

12 November 2023 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
MNMartje Van Neste
Martje Van Neste
ABAnnick Bogaerts
Annick Bogaerts
Nina NauwelaertsNina Nauwelaerts
Nina Nauwelaerts
JMJulia Macente
Julia Macente
ASAnne Smits
Anne Smits
Karel AllegaertKarel Allegaert
Karel Allegaert
Physiologically based pharmacokinetic (PBPK) modelling is a bottom-up approach to predict pharmacokinetics in specific populations based on population-specific and medicine-specific data. Using an illustrative approach, this review aims to highlight the challenges of incorporating physiological data to develop postpartum, lactating women and breastfed infant PBPK models. For instance, most women retain pregnancy weight during the postpartum period, especially after excessive gestational weight gain, while breastfeeding might be associated with lower postpartum weight retention and long-term weight control. Based on a structured search, an equation for human milk intake reported the maximum intake of 153 mL/kg/day in exclusively breastfed infants at 20 days, which correlates with a high risk for medicine reactions at 2–4 weeks in breastfed infants. Furthermore, the changing composition of human milk and its enzymatic activities could affect pharmacokinetics in breastfed infants. Growth in breastfed infants is slower and gastric emptying faster than in formula-fed infants, while a slower maturation of specific metabolizing enzymes in breastfed infants has been described. The currently available PBPK models for these populations lack structured systematic acquisition of population-specific data. Future directions include systematic searches to fully identify physiological data. Following data integration as mathematical equations, this holds the promise to improve postpartum, lactation and infant PBPK models.

10 April 2024 in BMJ Paediatrics Open
Verified
Journal Article
Open access
PDF file
MNMartje Van Neste
Martje Van Neste
Nina NauwelaertsNina Nauwelaerts
Nina Nauwelaerts
Michael CeulemansMichael Ceulemans
Michael Ceulemans
KCKristel Van Calsteren
Kristel Van Calsteren
AEAn Eerdekens
An Eerdekens
ASAnne Smits
Anne Smits
Introduction Breastfeeding is beneficial for the health of the mother and child. However, at least 50% of postpartum women need pharmacotherapy, and this number is rising due to the increasing prevalence of chronic diseases and pregnancies at a later age. Making informed decisions on medicine use while breastfeeding is often challenging, considering the extensive information gap on medicine exposure and safety during lactation. This can result in the unnecessary cessation of breastfeeding, the avoidance of pharmacotherapy or the off-label use of medicines. The UmbrelLACT study aims to collect data on human milk transfer of maternal medicines, child exposure and general health outcomes. Additionally, the predictive performance of lactation and paediatric physiologically based pharmacokinetic (PBPK) models, a promising tool to predict medicine exposure in special populations, will be evaluated. Methods and analysis Each year, we expect to recruit 5–15 breastfeeding mothers using pharmacotherapy via the University Hospitals Leuven, the BELpREG project (pregnancy registry in Belgium) or external health facilities. Each request and compound will be evaluated on relevance (ie, added value to available scientific evidence) and feasibility (including access to analytical assays). Participants will be requested to complete at least one questionnaire on maternal and child’s general health and collect human milk samples over 24 hours. Optionally, two maternal and one child’s blood samples can be collected. The maternal medicine concentration in human milk will be determined along with the estimation of the medicine intake (eg, daily infant dose and relative infant dose) and systemic exposure of the breastfed child. The predictive performance of PBPK models will be assessed by comparing the observed concentrations in human milk and plasma to the PBPK predictions. Ethics and dissemination This study has been approved by the Ethics Committee Research UZ/KU Leuven (internal study number S67204). Results will be published in peer-reviewed journals and presented at (inter)national scientific meetings. Trial registration number NCT06042803.

5 December 2024 in Nutrients
Verified
Journal Article
Open access
PDF file
LCLucas Cloostermans
Lucas Cloostermans
Karel AllegaertKarel Allegaert
Karel Allegaert
ASAnne Smits
Anne Smits
MNMartje Van Neste
Martje Van Neste
Background: Global health organizations recommend breastfeeding, but maternal pharmacotherapy can disrupt this due to safety concerns. Physiologically based pharmacokinetic (PBPK) models predict medication transfer through breastfeeding, relying on validated milk intake volume data. However, the literature is mainly focused on different measurement methods, or such intake data have been collected without systematic review. This systematic review therefore aims to gather data on human milk intake volume derived using the (dose-to-the-mother) deuterium oxide dilution method, allowing for comparison with the literature. Additionally, it aims to explore the effects of maternal conditions on milk intake volume. Methods: PubMed, Embase, Web of science, Cochrane library, Scopus and CINAHL were searched for studies on the dilution method and breastfeeding in healthy infants. Risk of bias was assessed using the Newcastle–Ottawa scale (NOS) and the Risk of Bias 2 (RoB2) tool. Data on mean human milk intake volume were extracted and synthesized (mL/day and mL/kg/day) throughout infancy. Results: Sixty studies (34 countries) reported on the milk intake volume of 5502 infants. This intake was best described by logarithmic regression y(mL/kg/day) = 149.4002 − 0.2268 × x − 0.1365 × log(x) (x = postnatal age, days). Maternal conditions showed no significant influence on human milk intake, except for maternal smoking (reduction). Conclusions: This function corresponds with previous research, particularly for infants aged between 1.5 and 12 months. The limited availability of early infancy data underscores the need for additional data for future PBPK modeling to enhance informed healthcare decisions and improve outcomes for mothers and infants.

8 March 2025 in Nutrients
Verified
Journal Article
Open access
PDF file
MNMartje Van Neste
Martje Van Neste
KVKatoo Verschoren
Katoo Verschoren
RKRani Marthe Kempenaers
Rani Marthe Kempenaers
AEAn Eerdekens
An Eerdekens
DKDanine Kitshoff
Danine Kitshoff
ABAnnick Bogaerts
Annick Bogaerts
Breastfeeding is associated with many health benefits, while its prevalence is determined by numerous factors, including socioeconomic status (SES). SES is the position of an individual on the socioeconomic scale, using occupation, education, income, place of residence, and wealth as key indicators. Since its interrelationship with health is complex, world region-specific insights into the relevant socioeconomic inequalities impacting breastfeeding practices are crucial to effectively address these. The purpose of this systematic review is, therefore, to explore SES indicators affecting breastfeeding initiation and duration in two different United Nations-defined regions, Western Europe and Southern Africa to assess (dis)similarities, as these can guide region-specific, targeted interventions to improve practices. A systematic literature search was conducted across seven databases, of which 47 articles were included. The risk of bias was assessed, and outcome data related to SES as well as breastfeeding initiation and duration were collected. Higher education consistently leads to better breastfeeding initiation outcomes, but economic constraints and employment in informal sectors hinder breastfeeding practices in Southern Africa. In Western Europe, supportive working conditions and a migration background have a positive impact, while employment status and income show rather mixed effects. Community, regional, and religious factors play significant, ambiguous roles. In South Africa, food insecurity, the living environment, and geographic location complicate breastfeeding. This systematic review highlights the significant influence of SES on breastfeeding initiation and duration in Western Europe and Southern Africa, while the specific factors indeed vary between both regions. This systematic review therefore illustrates the relevance of region-specific SES factors, impacting breastfeeding practices. Addressing these barriers with region-specific, targeted approaches may result in substantial progress toward achieving global breastfeeding goals. Registration: PROSPERO (CRD42023473433).

9 July 2025 in CPT: Pharmacometrics & Systems Pharmacology
Verified
Journal Article
Open access
JMJulia Macente
Julia Macente
Nina NauwelaertsNina Nauwelaerts
Nina Nauwelaerts
JBJustine Marine Badée
Justine Marine Badée
Rodolfo Hernandes BonanRodolfo Hernandes Bonan
Rodolfo Hernandes Bonan
MHMiao‐Chan Huang
Miao‐Chan Huang
PAPieter Annaert
Pieter Annaert
Physiologically‐based pharmacokinetic (PBPK) modeling can support decision‐making on maternal medication use during breastfeeding. This study aimed to enhance lactation PBPK models in two ways. First, the utility of integrating permeability‐ versus perfusion‐limited distribution to human milk was explored using the Simcyp Simulator. Secondly, for permeability‐limited models, drug‐specific bidirectional intrinsic clearance across the blood‐milk barrier, predicted from drug physicochemical properties, was incorporated into lactation PBPK models. Initially, reference PBPK models were developed and verified against published clinical data. Geometric Mean Fold Error (GMFE; ~accuracy) and Average Fold Error (AFE; ~bias) for these models ranged from 1.13–1.51 and 0.68–1.42, respectively. These verified models were then extended to lactation PBPK models applying either permeability‐ or perfusion‐limited assumptions for drug distribution across the blood‐milk barrier. The lactation PBPK models were applied to predict drug concentrations in human milk and relative infant doses (RID) for 11 small molecule drugs with diverse physicochemical and disposition profiles. The models successfully predicted observed plasma PK, human milk concentration‐time profiles, and milk‐to‐plasma ratios. Nine drugs had RID values below the safety threshold of 25%, while levetiracetam and nevirapine showed relatively higher RIDs (up to 21%). Based on these findings, a decision tree is proposed to guide the selection between permeability‐ or perfusion‐limited distribution models in future lactation PBPK applications using Simcyp. This workflow can be extended beyond the 11 model drugs evaluated, supporting broader infant risk assessment for maternal medication during lactation.